PROTACpedia
The search can be performed by various parameters such as Target name, UniProt ID, SMILES substructure or by various details regarding a publication.
Note that it is possible to narrow down the search results by querying several fields simultaneously.

The resulting PROTAC images are color coded: green - E3 binder, red - linker, blue - target binding ligand.
If you find this web server of interest, please also try PRosettaC.
Gene or Target name
UniProt Id
Ligand name
E3 Ligase
E3 Binder
PROTAC SMILES (substructure)
PROTAC Name
Author
Year
Pubmed or Patent number
Curator
Algorithm and overview: Nir London (nir.london@weizmann.ac.il)
Server: Jaime Prilusky (jaime.prilusky@weizmann.ac.il)
6 Representative
+35 Active PROTACs
+33 Inactive PROTACs
 DetailsDC50DmaxSource
Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016 Jan 11;55(2):807-10. PMID:26593377 DOI:10.1002/anie.201507634
Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016 Jan 11;55(2):807-10. PMID:26593377 DOI:10.1002/anie.201507634
Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016 Jan 11;55(2):807-10. PMID:26593377 DOI:10.1002/anie.201507634
Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016 Jan 11;55(2):807-10. PMID:26593377 DOI:10.1002/anie.201507634
Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016 Jan 11;55(2):807-10. PMID:26593377 DOI:10.1002/anie.201507634
Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016 Jan 11;55(2):807-10. PMID:26593377 DOI:10.1002/anie.201507634
Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016 Jan 11;55(2):807-10. PMID:26593377 DOI:10.1002/anie.201507634
Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016 Jan 11;55(2):807-10. PMID:26593377 DOI:10.1002/anie.201507634
Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016 Jan 11;55(2):807-10. PMID:26593377 DOI:10.1002/anie.201507634
Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016 Jan 11;55(2):807-10. PMID:26593377 DOI:10.1002/anie.201507634
Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016 Jan 11;55(2):807-10. PMID:26593377 DOI:10.1002/anie.201507634
Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016 Jan 11;55(2):807-10. PMID:26593377 DOI:10.1002/anie.201507634
Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016 Jan 11;55(2):807-10. PMID:26593377 DOI:10.1002/anie.201507634
Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016 Jan 11;55(2):807-10. PMID:26593377 DOI:10.1002/anie.201507634
Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016 Jan 11;55(2):807-10. PMID:26593377 DOI:10.1002/anie.201507634
Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016 Jan 11;55(2):807-10. PMID:26593377 DOI:10.1002/anie.201507634
Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016 Jan 11;55(2):807-10. PMID:26593377 DOI:10.1002/anie.201507634
Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016 Jan 11;55(2):807-10. PMID:26593377 DOI:10.1002/anie.201507634
Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016 Jan 11;55(2):807-10. PMID:26593377 DOI:10.1002/anie.201507634
Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016 Jan 11;55(2):807-10. PMID:26593377 DOI:10.1002/anie.201507634
Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016 Jan 11;55(2):807-10. PMID:26593377 DOI:10.1002/anie.201507634
Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016 Jan 11;55(2):807-10. PMID:26593377 DOI:10.1002/anie.201507634
Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016 Jan 11;55(2):807-10. PMID:26593377 DOI:10.1002/anie.201507634
~ 30 μM Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand. Bioorg Med Chem Lett. 2016 Oct 15;26(20):4865-4869. PMID:27666635 DOI:10.1016/j.bmcl.2016.09.041
~ 30 μM Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand. Bioorg Med Chem Lett. 2016 Oct 15;26(20):4865-4869. PMID:27666635 DOI:10.1016/j.bmcl.2016.09.041
Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand. Bioorg Med Chem Lett. 2016 Oct 15;26(20):4865-4869. PMID:27666635 DOI:10.1016/j.bmcl.2016.09.041
= 340 nM= 95 % Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation. Cancer Res. 2019 Sep 15;79(18):4744-4753. PMID:31311809 DOI:10.1158/0008-5472.CAN-19-1236
= 2 uM= 85 % Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation. Cancer Res. 2019 Sep 15;79(18):4744-4753. PMID:31311809 DOI:10.1158/0008-5472.CAN-19-1236
= 8.5 nM Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase. J Med Chem. 2019 Oct 24;62(20):9281-9298. PMID:31539241 DOI:10.1021/acs.jmedchem.9b01264
= 10.1 nM Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase. J Med Chem. 2019 Oct 24;62(20):9281-9298. PMID:31539241 DOI:10.1021/acs.jmedchem.9b01264
= 17.9 nM Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase. J Med Chem. 2019 Oct 24;62(20):9281-9298. PMID:31539241 DOI:10.1021/acs.jmedchem.9b01264
= 34.7 nM Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase. J Med Chem. 2019 Oct 24;62(20):9281-9298. PMID:31539241 DOI:10.1021/acs.jmedchem.9b01264
= 37.9 nM Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase. J Med Chem. 2019 Oct 24;62(20):9281-9298. PMID:31539241 DOI:10.1021/acs.jmedchem.9b01264
= 40.2 nM Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase. J Med Chem. 2019 Oct 24;62(20):9281-9298. PMID:31539241 DOI:10.1021/acs.jmedchem.9b01264
= 611 nM Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase. J Med Chem. 2019 Oct 24;62(20):9281-9298. PMID:31539241 DOI:10.1021/acs.jmedchem.9b01264
Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase. J Med Chem. 2019 Oct 24;62(20):9281-9298. PMID:31539241 DOI:10.1021/acs.jmedchem.9b01264
Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase. J Med Chem. 2019 Oct 24;62(20):9281-9298. PMID:31539241 DOI:10.1021/acs.jmedchem.9b01264
Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase. J Med Chem. 2019 Oct 24;62(20):9281-9298. PMID:31539241 DOI:10.1021/acs.jmedchem.9b01264
Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase. J Med Chem. 2019 Oct 24;62(20):9281-9298. PMID:31539241 DOI:10.1021/acs.jmedchem.9b01264
Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase. J Med Chem. 2019 Oct 24;62(20):9281-9298. PMID:31539241 DOI:10.1021/acs.jmedchem.9b01264
Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase. J Med Chem. 2019 Oct 24;62(20):9281-9298. PMID:31539241 DOI:10.1021/acs.jmedchem.9b01264
Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase. J Med Chem. 2019 Oct 24;62(20):9281-9298. PMID:31539241 DOI:10.1021/acs.jmedchem.9b01264
Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase. J Med Chem. 2019 Oct 24;62(20):9281-9298. PMID:31539241 DOI:10.1021/acs.jmedchem.9b01264
Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase. J Med Chem. 2019 Oct 24;62(20):9281-9298. PMID:31539241 DOI:10.1021/acs.jmedchem.9b01264
Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase. J Med Chem. 2019 Oct 24;62(20):9281-9298. PMID:31539241 DOI:10.1021/acs.jmedchem.9b01264
Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase. J Med Chem. 2019 Oct 24;62(20):9281-9298. PMID:31539241 DOI:10.1021/acs.jmedchem.9b01264
Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase. J Med Chem. 2019 Oct 24;62(20):9281-9298. PMID:31539241 DOI:10.1021/acs.jmedchem.9b01264
Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase. J Med Chem. 2019 Oct 24;62(20):9281-9298. PMID:31539241 DOI:10.1021/acs.jmedchem.9b01264
Azo-PROTAC: Novel Light-Controlled Small-Molecule Tool for Protein Knockdown. J Med Chem. 2020 May 14;63(9):4644-4654. PMID:32153174 DOI:10.1021/acs.jmedchem.9b02058
Azo-PROTAC: Novel Light-Controlled Small-Molecule Tool for Protein Knockdown. J Med Chem. 2020 May 14;63(9):4644-4654. PMID:32153174 DOI:10.1021/acs.jmedchem.9b02058
Azo-PROTAC: Novel Light-Controlled Small-Molecule Tool for Protein Knockdown. J Med Chem. 2020 May 14;63(9):4644-4654. PMID:32153174 DOI:10.1021/acs.jmedchem.9b02058
Azo-PROTAC: Novel Light-Controlled Small-Molecule Tool for Protein Knockdown. J Med Chem. 2020 May 14;63(9):4644-4654. PMID:32153174 DOI:10.1021/acs.jmedchem.9b02058
Azo-PROTAC: Novel Light-Controlled Small-Molecule Tool for Protein Knockdown. J Med Chem. 2020 May 14;63(9):4644-4654. PMID:32153174 DOI:10.1021/acs.jmedchem.9b02058
Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects. J Med Chem. 2020 Aug 13;63(15):8567-8583. PMID:32657579 DOI:10.1021/acs.jmedchem.0c00967
~ 10 nM Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects. J Med Chem. 2020 Aug 13;63(15):8567-8583. PMID:32657579 DOI:10.1021/acs.jmedchem.0c00967
~ 20 nM= 50 % Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects. J Med Chem. 2020 Aug 13;63(15):8567-8583. PMID:32657579 DOI:10.1021/acs.jmedchem.0c00967
~ 20 nM Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects. J Med Chem. 2020 Aug 13;63(15):8567-8583. PMID:32657579 DOI:10.1021/acs.jmedchem.0c00967
~ 56 nM Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects. J Med Chem. 2020 Aug 13;63(15):8567-8583. PMID:32657579 DOI:10.1021/acs.jmedchem.0c00967
~ 56 nM Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects. J Med Chem. 2020 Aug 13;63(15):8567-8583. PMID:32657579 DOI:10.1021/acs.jmedchem.0c00967
~ 56 nM Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects. J Med Chem. 2020 Aug 13;63(15):8567-8583. PMID:32657579 DOI:10.1021/acs.jmedchem.0c00967
~ 70 nM Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects. J Med Chem. 2020 Aug 13;63(15):8567-8583. PMID:32657579 DOI:10.1021/acs.jmedchem.0c00967
~ 70 nM Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects. J Med Chem. 2020 Aug 13;63(15):8567-8583. PMID:32657579 DOI:10.1021/acs.jmedchem.0c00967
~ 70 nM Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects. J Med Chem. 2020 Aug 13;63(15):8567-8583. PMID:32657579 DOI:10.1021/acs.jmedchem.0c00967
~ 200 nM Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects. J Med Chem. 2020 Aug 13;63(15):8567-8583. PMID:32657579 DOI:10.1021/acs.jmedchem.0c00967
~ 300 nM Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects. J Med Chem. 2020 Aug 13;63(15):8567-8583. PMID:32657579 DOI:10.1021/acs.jmedchem.0c00967
~ 400 nM Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects. J Med Chem. 2020 Aug 13;63(15):8567-8583. PMID:32657579 DOI:10.1021/acs.jmedchem.0c00967
~ 500 nM Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects. J Med Chem. 2020 Aug 13;63(15):8567-8583. PMID:32657579 DOI:10.1021/acs.jmedchem.0c00967
~ 625 nM Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects. J Med Chem. 2020 Aug 13;63(15):8567-8583. PMID:32657579 DOI:10.1021/acs.jmedchem.0c00967
> 625 nM Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects. J Med Chem. 2020 Aug 13;63(15):8567-8583. PMID:32657579 DOI:10.1021/acs.jmedchem.0c00967
Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects. J Med Chem. 2020 Aug 13;63(15):8567-8583. PMID:32657579 DOI:10.1021/acs.jmedchem.0c00967
Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects. J Med Chem. 2020 Aug 13;63(15):8567-8583. PMID:32657579 DOI:10.1021/acs.jmedchem.0c00967
Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects. J Med Chem. 2020 Aug 13;63(15):8567-8583. PMID:32657579 DOI:10.1021/acs.jmedchem.0c00967
Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects. J Med Chem. 2020 Aug 13;63(15):8567-8583. PMID:32657579 DOI:10.1021/acs.jmedchem.0c00967
Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects. J Med Chem. 2020 Aug 13;63(15):8567-8583. PMID:32657579 DOI:10.1021/acs.jmedchem.0c00967